Augmenting the clearance of bacterial products to reduce systemic inflammation.


Cyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe Infection and Sepsis

August 23, 2016

August 23rd, 2016 (Vancouver) - Cyon Therapeutics Inc.(Cyon) today announced that it has entered into a license agreement with Novartis AG (NYSE:NVS) for their anti-PCSK9 antibody, LGT-209. The licensing deal brings with it worldwide rights for use in SIRS (systemic inflammatory response syndrome) and the prevention and treatment of sepsis. Cyon plans to move immediately into...   Read More...

Doctors hope to repurpose cholesterol drug to treat often-deadly sepsis reactions

April 26, 2016

MEDIA COVERAGE: Article published in Vancouver Sun – April 24, 2016 Contact Cyon Fax: 604.806.8511 Email:

Cyon Celebrates Launch

June 2, 2014

The newest addition to Vancouver’s Biotechnology hub, Cyon Therapeutics was founded in May 2014 by three Physicians-Researchers. Dr. Russell, Dr. Walley and Dr. Boyd are recognized as world leaders in the area of organ damage due to severe infections. They observed that while antibiotics are essential to kill the bacteria in a serious infections, the...   Read More...
Go to Top of Page